The development of drug resistance is an almost universal characteristic of cancers, and is an outstanding challenge in the fields of tumor biology and clinical oncology. While there have been many studies focused on genomic contributions to resistance in cancer cells, recent studies have shown that genetically homogeneous cells can undergo adaptive cell state changes leading to the rapid emergence of drug-tolerant phenotypes. The heterogeneous nature of tumors, coupled with the functional and metabolic changes that accompany adaptive resistance development, suggests that multi-omic, single cell approaches have the potential to provide deep insights into the cell state changes that lead to adaptive resistance, and may provide hypotheses for new therapies and therapy combinations that can prevent resistance development. IsoPlexis’ multi-omic (metabolomics + functional proteomics) energy state application provides a critical and uniquely capable tool for addressing this biology.
Through the use of IsoPlexis’ multi-omic energy state application, independent trajectories to drug tolerance can be revealed, enabling researchers to better develop combination therapies to combat this drug-resistant cell state and prevent drug resistance.
Learn more about this groundbreaking innovative technology and its unique applications in this webinar.
Topics to be covered
Cellular, metabolic, and proteomic changes during drug treatment that lead to resistance
Using multi-omic approaches to reveal functional adaptations
Identifying and countering independent trajectories to drug tolerance
Tuesday, February 16, 2021
11:30 AM - 1:00 PM Eastern Time
Meet the speakers
James R. Heath, PhD President and Professor Institute for Systems Biology, Seattle
Sean Mackay CEO and Co-Founder IsoPlexis
Harnessing Single-Cell Multi-Omic Energy States for Integrated Cancer Biology Feb 16, 2021
Information you provide will be shared with the sponsors for this content. The Scientist or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
The Scientist c/o LabX Media Group 1000 N West Street, Suite 1200, Wilmington, Delaware, United States, 19801 Toll Free: 888.788.0328 | Phone: 705.528.6888 Email: firstname.lastname@example.org